Publicacións en colaboración con investigadores/as de University of Milan (23)

2023

  1. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

    Journal of Thrombosis and Haemostasis

  2. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

  3. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2020

  1. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

    Blood, Vol. 135, Núm. 5, pp. 381-386

  2. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

  3. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

    Leukemia

2016

  1. Investigating rare haematological disorders - A celebration of 10 years of the Sherlock Holmes symposia

    European Oncology and Haematology, Vol. 12, Núm. 1, pp. 55-61

2013

  1. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease

    Blood, Vol. 121, Núm. 12, pp. 2336-2339

2011

  1. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease

    Haemophilia

  2. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

    Haemophilia, Vol. 17, Núm. 4, pp. 630-635

2010

  1. The impact of bleeding history, von willebrand factor and PFA-100® on the diagnosis of type 1 von willebrand disease: Results from the european study MCMDM-1VWD

    British Journal of Haematology, Vol. 151, Núm. 3, pp. 245-251

  2. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD

    Thrombosis Research, Vol. 126, Núm. 3, pp. 227-231

2009

  1. Expression of 14 von Willebrand factor mutations identified in patients with type.1 von Willebrand disease from the MCMDM-1VWD study

    Journal of Thrombosis and Haemostasis, Vol. 7, Núm. 8, pp. 1304-1312

2008

  1. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)

    Journal of Thrombosis and Haemostasis, Vol. 6, Núm. 5, pp. 762-771

  2. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the european study: Molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)

    Blood, Vol. 111, Núm. 10, pp. 4979-4985

  3. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the European Study MCMDM-1VWD

    Blood, Vol. 111, Núm. 7, pp. 3531-3539

2007

  1. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1VWD)

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 4, pp. 715-721

  2. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)

    Blood, Vol. 109, Núm. 1, pp. 112-121

  3. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 7, pp. 1420-1430